We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
The concentration of cases and the preferences of judges motivate firms to file fewer motions, which can be good or bad depending on who you ask
The US government claimed Moderna should be immune from patent infringement under Section 1498, raising questions about when the doctrine applies
Paul Hastings led Mitsubishi Tanabe to victory over Novartis at the International Chamber of Commerce
The Patent Trial and Appeal Board found that claims in a Novartis patent were obvious over the prior art
Scott Frank, the IP CEO at AT&T, officially established the education and awareness-focused organisation after its inaugural board meeting
The claim, filed at the England and Wales High Court, follows lawsuits launched by Moderna in the US and Germany
Novartis’s planned SCOTUS appeal may be a long shot, but the case raises interesting Section 112 and procedural questions, say counsel
In-house panellists weighed up the most disruptive trends in IP, from the TRIPS waiver to the rise of remote working
Pharma counsel can look at suspicious packaging, online sellers and other signs to learn whether products are fake, say sources at Merck, Gilead and Organon
With the UPC almost here, pharma and biotech counsel are weighing the risks and rewards of the new system
UK Court of Appeal overturns Amazon judgment; GM takes Avanci patent licence; vaccine waiver draft released; IBM sues games maker
Sponsored
Sponsored
-
Sponsored by Wanhuida Intellectual PropertyJianhui Li and Honghui Hu of Wanhuida Intellectual Property discuss the antitrust scrutiny of China’s Supreme People’s Court in a patent infringement appeal concerning reverse payment settlement agreement
-
Sponsored by Purplevine IPXiaojuan Yu of Purplevine IP Group discusses the medical device industry in China and considers why changes to the law are welcomed
-
Sponsored by FB RiceLee Miles of FB Rice discusses Australia’s patent box scheme which is set to introduce the agricultural and low emissions technology sectors
Counsel at innovator and generics brands debate the implications of attacks on product hopping, settlement restrictions, FDA-USPTO collaboration, and more
An EPO Board of Appeal ruling on how patentees can avoid disclosing prior art from clinical trials is welcome, but issues remain for future spats, counsel say
Law firm Susman Godfrey’s John Lahad explains how his firm and its co-counsel snagged a $42 million verdict for the University of Texas System and TissueGen
Counsel welcome the Delhi High Court’s clarity on claim amendment but worry that its interpretation of the Patents Act negates statutory law
Interviews; Exclusives
Interviews; Exclusives
Dagg tells Managing IP about being starstruck when dealing with Nobel Prize-winning inventors, and how she deals with self-doubt
-
Opinion: Indian domestic policy must match WTO stand on IP waivers
India has been both urging for vaccine waivers before the WTO and refusing compulsory licensing in the country, but it’s not helping anyone